Ondansétron Viatris (Ondansetron)

Ondansetron, the active ingredient in Ondansétron Viatris, is a serotonin 5‑HT3 receptor antagonist presented as a tablet for oral use. It is used to prevent nausea and vomiting associated with chemotherapy, radiotherapy and postoperative recovery in adults and children.

GNH USA supplies Ondansétron Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Ondansetron is employed across several clinical pathways that involve emesis control: - Chemotherapy‑induced nausea and vomiting (CINV): helps reduce the frequency and severity of nausea and vomiting in patients receiving moderately to highly emetogenic chemotherapy. - Radiotherapy‑induced nausea and vomiting (RINV): provides prophylactic relief for patients undergoing radiation treatment. - Post‑operative nausea and vomiting (PONV): reduces incidence of nausea and vomiting after surgical procedures. - Hyperemesis gravidarum (severe morning sickness): used off‑label in some regions to control persistent vomiting during pregnancy.

Ondansetron is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Diarrhoea: loose stools. - Fatigue: feeling of tiredness. - Dizziness: light‑headed sensation.

Serious or Rare Side Effects: - QT prolongation: abnormal heart rhythm that may lead to arrhythmia. - Severe allergic reaction: rash, itching, swelling, or difficulty breathing. - Serotonin syndrome: rare when combined with other serotonergic agents. - Hepatic dysfunction: elevated liver enzymes. - Vision changes: blurred vision or visual disturbances.

Before prescribing Ondansetron, consider the following safety points: - Cardiac assessment: avoid use in patients with known prolonged QT interval or significant cardiac disease. - Electrolyte balance: correct hypokalaemia or hypomagnesemia which can predispose to arrhythmia. - Concomitant serotonergic drugs: monitor for signs of serotonin syndrome. - Liver impairment: dose adjustment may be required in moderate to severe hepatic dysfunction. - Pregnancy and lactation: weigh benefits against potential risks; use only if clearly needed. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Ondansetron may interact with several medicines; monitoring is advised.

Major Interactions (Avoid): - Apixaban, Rivaroxaban, Dabigatran: increased risk of bleeding. - Tramadol and other opioids: heightened risk of serotonin syndrome. - Amiodarone and other QT‑prolonging agents: additive effect on QT interval.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., fluconazole): may increase ondansetron plasma levels. - Antidepressants (SSRIs, SNRIs): potential for serotonin syndrome. - Anticonvulsants (carbamazepine, phenytoin): may reduce ondansetron effectiveness.